^
Association details:
| Biomarker: | CD20 positive |
|---|---|
| Cancer: | Childhood B Acute Lymphoblastic Leukemia |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
12/02/2021
Excerpt:
RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of...Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) (1.1)...Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy.
Secondary therapy:
Chemotherapy
